Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 3
2014 9
2015 8
2016 8
2017 9
2018 6
2019 13
2020 12
2021 12
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Citations

6 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A, Rijavec E, Grossi F. Indini A, et al. Among authors: rijavec e. Int J Mol Sci. 2021 Apr 30;22(9):4774. doi: 10.3390/ijms22094774. Int J Mol Sci. 2021. PMID: 33946310 Free PMC article. Review.
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are …
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mut …
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. Ready NE, et al. Among authors: rijavec e. J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127. J Immunother Cancer. 2023. PMID: 36725084 Free PMC article. Clinical Trial.
BACKGROUND: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern Cooperative Onc …
BACKGROUND: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-smal …
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
INTRODUCTION: Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its overexpression occurs in more than half the cases. ...Subsequently, they describe the mo …
INTRODUCTION: Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-small cell lung cancers. Although activat …
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) w …
BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non- …
Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.
Rijavec E, Coco S, Genova C, Rossi G, Longo L, Grossi F. Rijavec E, et al. Cancers (Basel). 2019 Dec 19;12(1):17. doi: 10.3390/cancers12010017. Cancers (Basel). 2019. PMID: 31861557 Free PMC article. Review.
Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. ...
Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis …
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
Coco S, Boccardo S, Mora M, Fontana V, Vanni I, Genova C, Alama A, Salvi S, Dal Bello MG, Bonfiglio S, Rijavec E, Sini C, Barletta G, Biello F, Carli F, Cavalieri Z, Burrafato G, Longo L, Ballestrero A, Grossi F. Coco S, et al. Among authors: rijavec e. Clin Breast Cancer. 2021 Jun;21(3):218-230.e6. doi: 10.1016/j.clbc.2020.09.001. Epub 2020 Sep 6. Clin Breast Cancer. 2021. PMID: 33008754
PATIENTS AND METHODS: Thirty-seven breast cancer survivors with unrelated lung cancer and 84 control subjects comprising women with breast cancer (42/84) or lung cancer (42/84) were enrolled. ...RESULTS: Estrogen receptor was expressed in …
PATIENTS AND METHODS: Thirty-seven breast cancer survivors with unrelated lung cancer and 84 control subjects comprisin …
Hematopoietic growth factors in lung cancer.
Genova C, Rijavec E, Grossi F. Genova C, et al. Among authors: rijavec e. Curr Opin Oncol. 2016 Mar;28(2):135-44. doi: 10.1097/CCO.0000000000000268. Curr Opin Oncol. 2016. PMID: 26742020 Review.
PURPOSE OF REVIEW: Most patients affected by lung cancer are treated with chemotherapy, and hence are at risk of myelosuppression. ...The most recent international guidelines address these characteristics and include the main indications for hematologic growth facto …
PURPOSE OF REVIEW: Most patients affected by lung cancer are treated with chemotherapy, and hence are at risk of myelosuppress …
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C, Rossi G, Tagliamento M, Rijavec E, Biello F, Cerbone L, Zullo L, Grossi F. Genova C, et al. Among authors: rijavec e. Expert Rev Respir Med. 2020 Apr;14(4):367-383. doi: 10.1080/17476348.2020.1714441. Epub 2020 Jan 17. Expert Rev Respir Med. 2020. PMID: 31917616 Review.
Introduction: The discovery of new actionable oncogenic drivers has led to the development of effective antineoplastic targeted agents in advanced non-small cell lung cancer (NSCLC). While the role of inhibitors of the epidermal growth factor receptor (EGFR), anapla …
Introduction: The discovery of new actionable oncogenic drivers has led to the development of effective antineoplastic targeted agents in ad …
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S. Genova C, et al. Among authors: rijavec e. Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832. Cells. 2023. PMID: 36980174 Free PMC article.
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). ...
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors ( …
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Banna GL, Tiseo M, Cortinovis DL, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A. Banna GL, et al. Among authors: rijavec e. Thorac Cancer. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22. Thorac Cancer. 2022. PMID: 34939342 Free PMC article.
BACKGROUND: Patients with programmed cell death-ligand 1 (PD-L1) 50% metastatic non-small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first-line immunotherapy have heterogeneous clinical assessment and outcomes. METHODS: To explore t …
BACKGROUND: Patients with programmed cell death-ligand 1 (PD-L1) 50% metastatic non-small cell lung cancer (mNSCLC) and ECOG p …
81 results